Chemed (NYSE:CHE) Issues FY 2026 Earnings Guidance

Chemed (NYSE:CHE) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 25.000-25.750 for the period, compared to the consensus EPS estimate of 24.010. The company issued revenue guidance of -.

Chemed Stock Up 1.3%

Shares of CHE stock traded up $6.75 during mid-day trading on Tuesday, hitting $516.09. 198,346 shares of the stock traded hands, compared to its average volume of 222,962. Chemed has a 52-week low of $365.20 and a 52-week high of $520.01. The stock has a market cap of $6.85 billion, a P/E ratio of 28.12, a P/E/G ratio of 1.88 and a beta of 0.52. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.85 and a quick ratio of 0.83. The stock’s fifty day moving average is $459.92 and its two-hundred day moving average is $434.09.

Chemed Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, May 28th. Chemed’s payout ratio is currently 13.08%.

Analysts Set New Price Targets

CHE has been the subject of several analyst reports. Bank of America increased their price objective on Chemed from $450.00 to $510.00 and gave the company a “neutral” rating in a report on Thursday, July 9th. Royal Bank Of Canada upped their target price on Chemed from $422.00 to $436.00 and gave the company a “sector perform” rating in a research report on Monday, April 27th. Weiss Ratings upgraded Chemed from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, July 17th. Wall Street Zen cut Chemed from a “buy” rating to a “hold” rating in a research note on Monday, June 8th. Finally, Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $480.25.

Insider Transactions at Chemed

In other Chemed news, Director Andrea R. Lindell sold 1,347 shares of Chemed stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $447.33, for a total transaction of $602,553.51. Following the completion of the sale, the director owned 4,578 shares of the company’s stock, valued at approximately $2,047,876.74. The trade was a 22.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $421.13, for a total value of $842,260.00. Following the sale, the chief executive officer owned 90,219 shares in the company, valued at approximately $37,993,927.47. The trade was a 2.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 3.33% of the company’s stock.

Institutional Trading of Chemed

Several institutional investors and hedge funds have recently bought and sold shares of CHE. AQR Capital Management LLC raised its holdings in shares of Chemed by 89.2% during the fourth quarter. AQR Capital Management LLC now owns 325,579 shares of the company’s stock worth $139,302,000 after purchasing an additional 153,469 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Chemed by 1,260.2% in the fourth quarter. Victory Capital Management Inc. now owns 117,685 shares of the company’s stock valued at $50,353,000 after purchasing an additional 109,033 shares during the last quarter. Arrowstreet Capital Limited Partnership grew its position in Chemed by 740.9% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 95,573 shares of the company’s stock worth $42,792,000 after purchasing an additional 84,208 shares during the period. Epoch Investment Partners Inc. grew its position in Chemed by 29.4% during the 3rd quarter. Epoch Investment Partners Inc. now owns 307,275 shares of the company’s stock worth $137,579,000 after purchasing an additional 69,878 shares during the period. Finally, Millennium Management LLC raised its stake in shares of Chemed by 72.4% during the 4th quarter. Millennium Management LLC now owns 137,146 shares of the company’s stock valued at $58,679,000 after buying an additional 57,614 shares during the last quarter. 95.85% of the stock is currently owned by institutional investors and hedge funds.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.